Final draft guidance recommends D‑VRd on the NHS in England and Wales
News
Anocca doses first patients with precision TCR‑T therapy
Company begins phase 1 treatment in multi‑centre VIDAR‑1 trial
Connecta launches phase 2a trial of neuroplasticity modulator
Study marks major milestone for CTH120 as company advances disease‑modifying ambitions
Aquipta recommended by NICE for acute migraine treatment
Guidance paves the way for NHS access for eligible adults in England and Wales
Talvey accepted for use in Scotland for relapsed and refractory multiple myeloma
SMC backs first GPRC5D‑targeting bispecific for patients after three or more treatments
Alzecure enters collaboration and with Lilly for Alzheimer’s project
Partnership grants Lilly global rights to Alzstatin ACD680
Survodutide trial data show targeted visceral and liver fat reductions
Phase 3 results highlight metabolic benefits alongside weight loss
Johnson & Johnson reports phase 2 data showing nipocalimab reduced SLE disease activity
Late‑breaking EULAR results highlight sustained responses through week 52
European approval enables measles protection with CSL’s immunoglobulin Privigen
Commission authorisation expands access to passive measles prophylaxis for vulnerable patients
JJP Biologics reports positive interim phase 1b data for nebaprubart
Early clinical activity supports expansion into broader IgA‑mediated conditions
Immunotherapy boost can spare more bladder cancer patients major surgery
Adding durvalumab to chemoradiation helps people avoid having their bladder removed
Deep Science Ventures and MDC partner to accelerate brain treatments
New collaboration aims to break barriers in brain‑targeted drug discovery
Aragen to manufacture Renaissance Pharma’s FDA Fast Track mAb
Aragen scales Daretabart to commercial-ready production following rapid 9‑month tech transfer
Pierre Fabre Laboratories secures CHMP backing for first‑line BRAFTOVI regimen
Data shows survival benefit in BRAFV600E‑mutant metastatic colorectal cancer
Resolution Therapeutics hails positive 4‑year MATCH data in liver cirrhosis
Findings strengthen rationale for EMERALD trial of engineered macrophage therapy RTX001
